Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.109741 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Ildiko Bock-Marquette und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Medical Chemistry, University of Pecs, Medical School, Pecs H-7624, Hungary; Szentagothai Research Centre, Research Gr…. Hauptthemen laut MEDLINE: Myocardial Infarction, Thymosin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Our dream of defeating the processes of organ damage and aging remains a challenge scientists pursued for hundreds of years. Although the goal is to successfully treat the body as a whole, steps towards regenerating individual organs are even considered significant. Since initial approaches utilizing only progenitor cells appear limited, we propose interconnecting our collective knowledge regarding aging and embryonic development may lead to the discovery of molecules which provide alternatives to effectively reverse cellular damage. In this review, we introduce and summarize our results regarding Thymosin beta-4 (TB4) to support our hypothesis using the heart as model system. Accordingly, we investigated the developmental expression of TB4 in mouse embryos and determined the impact of the molecule in adult animals by systemically injecting the peptide following acute cardiac infarction or with no injury. Our results proved, TB4 is expressed in the developing heart and promotes cardiac cell migration and survival. In adults, the peptide enhances myocyte survival and improves cardiac function after coronary artery ligation. Moreover, intravenous injections of TB4 alter the morphology of the adult epicardium, and the changes resemble the characteristics of the embryo. Reactivation of the embryonic program became equally reflected by the increased number of cardiac vessels and by the alteration of the gene expression profile typical of the embryonic state. Moreover, we discovered TB4 is capable of epicardial progenitor activation, and revealed the effect is independent of hypoxic injury. By observing the above results, we believe, further discoveries and consequential postnatal administration of developmentally relevant candidate molecules such as TB4 may likely result in reversing aging processes and accelerate organ regeneration in the human body.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Medical Chemistry, University of Pecs, Medical School, Pecs H-7624, Hungary; Szentagothai Research Centre, Research Group of Regenerative Science, Sport and Medicine, University of Pecs, P…
- Department of Molecular Biology, Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Gladstone Institute of Cardiovascular Disease and Roddenberry Stem Cell Center, Department of Biochemistry & Biophysics, University of California San Francisco, San Francisco, CA 94158, USA.
Zitieren
APA
Bock-Marquette, I., Maar, K., Maar, S., Lippai, B., Faskerti, G., Gallyas, F., Olson, E. N., & Srivastava, D. (2023). Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.109741
Vancouver
Bock-Marquette I, Maar K, Maar S, Lippai B, Faskerti G, Gallyas F, et al. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.109741
BibTeX
@article{BockMarquette2023,
author = {Bock-Marquette, Ildiko and Maar, Klaudia and Maar, Szabolcs and Lippai, Balint and Faskerti, Gabor and Gallyas, Ferenc and Olson, Eric N and Srivastava, Deepak},
title = {Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.109741}
}
EUVIMED